PML-RARA Fusion Detection by FISH at Chughtai Lab

PML-RARA Fusion Detection by FISH at Chughtai Lab

PML-RARA Fusion Detection by Fluorescence In Situ Hybridization (FISH) is a highly specialized molecular cytogenetic test performed to detect the reciprocal translocation between chromosomes 15 and 17, denoted as t(15;17)(q24;q21). This specific genetic rearrangement results in the fusion of the Promyelocytic Leukemia (PML) gene on chromosome 15 with the Retinoic Acid Receptor Alpha (RARA) gene on chromosome 17. The presence of the PML-RARA fusion gene is the diagnostic hallmark of Acute Promyelocytic Leukemia (APL), a distinct and clinically aggressive subtype of Acute Myeloid Leukemia (AML) classified as AML-M3 in the French-American-British (FAB) classification system. Identifying this fusion gene is critical because APL is characterized by a severe, life-threatening hemorrhagic diathesis that requires immediate medical intervention. However, it is also highly treatable with targeted therapies such as All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO).

The FISH technique utilizes fluorescently labeled DNA probes that specifically bind to complementary target sequences on chromosomes 15 and 17. Under a specialized fluorescence microscope, clinical pathologists and cytogeneticists can visualize the physical location of these genes. In a normal cell, the PML and RARA genes appear as separate fluorescent signals (typically green and red). In a cell harboring the t(15;17) translocation, the fusion of these two genes brings the fluorescent probes into close proximity, creating a merged signal (typically yellow or a closely paired red-green signal). This molecular evaluation provides rapid, highly sensitive, and exceptionally specific results, which are vital for guiding immediate clinical decisions in hematology-oncology departments across Pakistan.

Clinical Procedure: What to Expect

Patient Preparation

Patient preparation for the PML-RARA Fusion Detection by FISH depends primarily on the specimen type requested by the referring hematologist or oncologist. The test can be performed on either peripheral blood or bone marrow aspirate samples. Patients should observe the following preparation guidelines:

• No Fasting Required: There is generally no requirement to fast before providing a peripheral blood or bone marrow sample. Patients may eat and drink normally unless instructed otherwise by their physician.
• Medication Review: Patients must inform their healthcare provider of all current medications, especially anticoagulants (blood thinners) like warfarin, heparin, aspirin, or clopidogrel, as these can increase the risk of bleeding during bone marrow aspiration.
• Consent and Medical History: For bone marrow aspiration, a formal written consent is mandatory. The clinical team will review the patient’s medical history, focusing on bleeding disorders or previous reactions to local anesthetics.
• Comfortable Clothing: If a bone marrow biopsy or aspiration is scheduled, patients are advised to wear loose, comfortable clothing to facilitate easy access to the posterior superior iliac spine (hip bone).

During the Procedure

The collection process varies significantly based on whether peripheral blood or bone marrow is utilized as the diagnostic specimen:

• Peripheral Blood Collection: A phlebotomist performs a standard venipuncture, typically drawing 3 to 5 mL of blood into an EDTA (purple top) or sodium heparin (green top) tube. The site is cleansed with an antiseptic, a tourniquet is applied, the needle is inserted, and the sample is collected. The procedure takes less than five minutes and involves minimal discomfort.
• Bone Marrow Aspiration: This procedure is performed by a qualified hematologist or trained clinical specialist under strict sterile conditions. The patient is positioned on their side or stomach. The skin over the posterior superior iliac spine is thoroughly cleansed with an antiseptic solution. A local anesthetic (usually lidocaine) is injected to numb the skin and the periosteum (the outer surface of the bone). A specialized bone marrow aspiration needle is then inserted through the bone cortex into the marrow cavity. A small volume of liquid bone marrow (approximately 1 to 2 mL) is aspirated into a syringe. Patients may experience a brief, sharp pulling or sucking sensation during aspiration.
• Laboratory Processing: Once received by the molecular diagnostics division at Chughtai Lab, the specimen undergoes cell harvesting. Cells are dropped onto glass slides, fixed, and treated. Dual-color, dual-fusion PML-RARA DNA probes are applied to the slides. The DNA is denatured and allowed to hybridize overnight in a controlled thermal environment. Post-hybridization washes are performed to remove unbound probes, and the cell nuclei are counterstained with DAPI.
• Microscopic Analysis: An experienced cytogeneticist analyzes at least 200 interphase nuclei and, if available, metaphase spreads using a high-resolution fluorescence microscope equipped with specialized optical filters. The presence, absence, and spatial configuration of the fluorescent signals are meticulously recorded.

When is a PML-RARA Fusion Detection by FISH Performed?

Diagnosis of Suspected Acute Promyelocytic Leukemia

Physicians urgently request this test when a patient presents with clinical signs, symptoms, and initial laboratory findings highly suggestive of Acute Promyelocytic Leukemia (APL). These findings typically include severe unexplained bruising, mucosal bleeding, epistaxis, prolonged bleeding from venipuncture sites, marked thrombocytopenia, anemia, leukopenia (or sometimes leukocytosis), and the presence of abnormal promyelocytes with abundant Auer rods (sometimes in bundles called “faggot cells”) on the peripheral blood smear. Because APL is associated with a catastrophic risk of disseminated intravascular coagulation (DIC), rapid confirmation via FISH is essential to initiate life-saving differentiation therapy immediately.

Rapid Differentiation of Acute Myeloid Leukemia Subtypes

Acute Myeloid Leukemia is a heterogeneous group of hematologic malignancies with vastly different treatment protocols and prognoses. While conventional cytogenetics (karyotyping) can take 7 to 14 days to yield results, FISH for PML-RARA provides diagnostic confirmation within 24 to 48 hours. This rapid turnaround time allows oncologists to differentiate APL from other AML subtypes quickly. This distinction is critical because the standard chemotherapy regimens used for other AML subtypes can exacerbate the coagulopathy in APL patients, potentially leading to fatal intracranial or pulmonary hemorrhages if started without ATRA cover.

Assessment of Minimal Residual Disease

Following the completion of induction and consolidation therapy, physicians utilize PML-RARA FISH to evaluate the presence of Minimal Residual Disease (MRD). MRD refers to the small number of leukemic cells that remain in the bone marrow or blood after treatment, which cannot be detected by routine microscopic examination of blood or bone marrow smears. Detecting persistent PML-RARA positive cells indicates that the disease has not been completely eradicated, prompting clinicians to consider treatment intensification, maintenance therapy modification, or alternative therapeutic strategies such as stem cell transplantation.

Monitoring Response to Targeted Therapies

The introduction of targeted agents like All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO) has revolutionized the treatment of APL, turning it from one of the most lethal leukemias into one of the most curable. PML-RARA FISH is performed at specific clinical intervals during and after therapy to monitor the patient’s cytogenetic response. A gradual decrease and eventual disappearance of the PML-RARA fusion signal confirm a molecular response to the targeted regimen, validating the efficacy of the ongoing therapeutic protocol.

Early Detection of Clinical Relapse

For patients in complete hematologic remission, routine surveillance using PML-RARA detection is standard clinical practice. If a patient who previously tested negative for the PML-RARA fusion gene begins to show positive signals during routine follow-up FISH testing, it indicates a molecular relapse. Detecting relapse at the molecular level, before the patient develops clinical symptoms or abnormal blood counts, allows for early therapeutic intervention, which significantly improves the chances of re-inducing a durable remission.

What Does a PML-RARA Fusion Detection by FISH Detect?

The PML-RARA Fusion Detection by FISH is designed to identify specific cytogenetic configurations and abnormalities within the patient’s cells. The test detects and characterizes the following parameters:

• Typical t(15;17) Translocation: The classic reciprocal translocation resulting in two fusion signals (one on the derivative chromosome 15 and one on the derivative chromosome 17), confirming standard APL.
• Atypical or Variant Translocations: Complex rearrangements involving chromosomes 15 and 17 along with a third or fourth chromosome.
• Cryptic PML-RARA Rearrangements: Submicroscopic insertions or rearrangements that are cytogenetically invisible on a standard karyotype but detectable by highly sensitive FISH probes.
• PML-RARA Deletions: Deletions of the fusion gene or adjacent chromosomal regions on the derivative chromosomes.
• Normal Diploid Pattern: The presence of two normal independent PML signals and two normal independent RARA signals, indicating the absence of the t(15;17) translocation.
• Hyperdiploidy or Polyploidy: Multiple copies of normal or rearranged chromosomes 15 and 17 within the analyzed nuclei.
• Clonal Evolution: The emergence of secondary cytogenetic abnormalities alongside the primary PML-RARA fusion clone, which may impact prognosis.
• Percentage of Positive Nuclei: The exact proportion of interphase cells displaying the fusion signal, which is critical for quantifying tumor burden.
• Dual-Fusion Signal Patterns: The specific visual configuration of two fusion signals, one free red signal, and one free green signal (2F1R1G), confirming a classic dual-fusion pattern.
• Single-Fusion Signal Patterns: A variant pattern showing only one fusion signal, which can occur due to submicroscopic deletions of the reciprocal fusion product.
• Therapy-Induced Cytogenetic Changes: Changes in the clonal population following exposure to chemotherapy or targeted agents.
• Background Noise Cutoff Limits: Verification that the observed fusion signals exceed the laboratory’s established normal cutoff threshold for false-positive signals.
• Metaphase Signal Localization: Precise localization of the fusion signals to the specific chromosomal bands during metaphase, confirming structural integrity.
• Atypical RARA Rearrangements: Rearrangements of the RARA gene with partner genes other than PML, such as ZBTB16 (PLZF), NUMA1, NPM1, or STAT5B, which can cause ATRA-resistant APL-like syndromes.
• PML Gene Amplification: Rare cases showing multiple copies of the PML gene without fusion to RARA.
• RARA Gene Amplification: Increased copy numbers of the RARA locus on chromosome 17.
• Monosomy 15 or 17: The loss of one copy of chromosome 15 or 17, which can coexist with the translocation.
• Trisomy 15 or 17: The gain of an extra copy of chromosome 15 or 17.
• Isochromosome 17q: A structural abnormality involving the long arm of chromosome 17, which is a recognized secondary abnormality in APL.
• Minimal Residual Disease Status: The presence of low-level positive fusion signals in post-treatment specimens, indicating residual leukemic clones.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to providing rapid and highly accurate diagnostic reporting, recognizing that PML-RARA detection is often an emergency clinical request. The turnaround time for PML-RARA Fusion Detection by FISH is typically 3 to 5 working days. This timeline is necessary to ensure precise cell culture, hybridization, microscopic analysis of at least 200 cells, and double-reporting by qualified molecular pathologists.

Patients and referring physicians can access reports seamlessly through multiple digital channels. Once the report is finalized and signed off by the consultant pathologist, an automated SMS notification containing a direct download link is sent to the patient’s registered mobile number. Reports can also be accessed and downloaded via the official Chughtai Lab website portal or the Chughtai Lab mobile application. Physical copies of the reports can be collected from any Chughtai Lab collection center across Pakistan or delivered via home delivery services where available.

PML-RARA Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
PML-RARA Fusion Signal	Negative (No fusion signals observed; separate red and green signals)	Positive (Presence of merged yellow/orange or adjacent red-green fusion signals)
Signal Pattern (Dual-Color Dual-Fusion)	Two normal red (RARA) and two normal green (PML) signals (2R2G)	Two fusion, one red, and one green signal (2F1R1G) or atypical variant patterns
Percentage of Positive Cells	Below the laboratory’s established normal cutoff (typically < 1-2%)	Elevated percentage (ranging from 5% to 100% of analyzed nuclei)
RARA Gene Status	Two intact copies of the RARA gene on chromosome 17q21	Rearranged RARA gene fused with PML or alternative partner genes (e.g., PLZF)
PML Gene Status	Two intact copies of the PML gene on chromosome 15q24	Rearranged PML gene fused with RARA or deleted/altered loci
Metaphase Analysis	Normal chromosomal localization of PML and RARA probes	Visual confirmation of t(15;17) translocation on metaphase spreads
Secondary Cytogenetic Abnormalities	None detected	Presence of trisomy 8, isochromosome 17q, or other clonal abnormalities

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for PML-RARA Fusion Detection?

• CAP-Accredited Quality Standards: Chughtai Lab adheres to rigorous international quality control standards, ensuring high precision in molecular cytogenetic testing.
• Expert Molecular Pathologists: Reports are analyzed and signed off by highly experienced consultant pathologists specializing in hematopathology and molecular diagnostics.
• Advanced FISH Technology: The laboratory utilizes state-of-the-art fluorescence microscopes and high-affinity, FDA-approved DNA probes for superior signal resolution.
• Rapid Turnaround Time: Recognizing the clinical urgency of suspected APL, Chughtai Lab prioritizes PML-RARA testing to deliver results as quickly as possible.
• Extensive Collection Network: With hundreds of collection centers across Pakistan, patients can easily submit samples or undergo blood draws close to home.
• Convenient Home Sample Collection: Chughtai Lab offers professional home sample collection services, allowing patients to have their blood drawn in the comfort of their homes.
• Seamless Digital Report Access: Patients and oncologists can access, download, and share reports instantly via SMS, the Chughtai Lab app, or the online web portal.
• Comprehensive Diagnostic Support: Chughtai Lab offers a complete range of supporting tests, including complete blood counts (CBC), bone marrow biopsies, flow cytometry, and RT-PCR, providing a one-stop diagnostic solution.